Logo image of RPTX

REPARE THERAPEUTICS INC (RPTX) Stock Fundamental Analysis

NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock - Currency: USD

1.25  -0.08 (-6.02%)

After market: 1.28 +0.03 (+2.4%)

Fundamental Rating

3

RPTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. RPTX has a great financial health rating, but its profitability evaluates not so good. RPTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RPTX has reported negative net income.
In the past year RPTX has reported a negative cash flow from operations.
RPTX had negative earnings in each of the past 5 years.
RPTX had negative operating cash flow in 4 of the past 5 years.
RPTX Yearly Net Income VS EBIT VS OCF VS FCFRPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -47.98%, RPTX perfoms like the industry average, outperforming 48.68% of the companies in the same industry.
RPTX has a better Return On Equity (-56.04%) than 61.90% of its industry peers.
Industry RankSector Rank
ROA -47.98%
ROE -56.04%
ROIC N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
RPTX Yearly ROA, ROE, ROICRPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPTX Yearly Profit, Operating, Gross MarginsRPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

7

2. Health

2.1 Basic Checks

RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
RPTX has more shares outstanding than it did 1 year ago.
RPTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPTX Yearly Shares OutstandingRPTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPTX Yearly Total Debt VS Total AssetsRPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.49, we must say that RPTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.49, RPTX perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.49
ROIC/WACCN/A
WACC8.92%
RPTX Yearly LT Debt VS Equity VS FCFRPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.77 indicates that RPTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.77, RPTX is in the better half of the industry, outperforming 67.72% of the companies in the same industry.
RPTX has a Quick Ratio of 6.77. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
RPTX has a Quick ratio of 6.77. This is in the better half of the industry: RPTX outperforms 68.08% of its industry peers.
Industry RankSector Rank
Current Ratio 6.77
Quick Ratio 6.77
RPTX Yearly Current Assets VS Current LiabilitesRPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.31% over the past year.
Looking at the last year, RPTX shows a small growth in Revenue. The Revenue has grown by 4.56% in the last year.
RPTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 91.62% yearly.
EPS 1Y (TTM)10.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)4.56%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, RPTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.74% on average per year.
Based on estimates for the next years, RPTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.36%
EPS Next 2Y5.33%
EPS Next 3Y-6.24%
EPS Next 5Y16.74%
Revenue Next Year-83.4%
Revenue Next 2Y-57.83%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RPTX Yearly Revenue VS EstimatesRPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2030 20M 40M 60M 80M 100M
RPTX Yearly EPS VS EstimatesRPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RPTX. In the last year negative earnings were reported.
Also next year RPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPTX Price Earnings VS Forward Price EarningsRPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPTX Per share dataRPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as RPTX's earnings are expected to decrease with -6.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.33%
EPS Next 3Y-6.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REPARE THERAPEUTICS INC

NASDAQ:RPTX (4/25/2025, 8:00:01 PM)

After market: 1.28 +0.03 (+2.4%)

1.25

-0.08 (-6.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-13 2025-05-13/amc
Inst Owners72.52%
Inst Owner Change-44.63%
Ins Owners1.09%
Ins Owner Change2.33%
Market Cap53.14M
Analysts80
Price Target6.63 (430.4%)
Short Float %2.06%
Short Ratio2.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.8%
Min EPS beat(2)8.83%
Max EPS beat(2)16.77%
EPS beat(4)4
Avg EPS beat(4)451.3%
Min EPS beat(4)7.44%
Max EPS beat(4)1772.17%
EPS beat(8)6
Avg EPS beat(8)229.35%
EPS beat(12)8
Avg EPS beat(12)176.77%
EPS beat(16)9
Avg EPS beat(16)130.41%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-57.56%
Min Revenue beat(4)-100%
Max Revenue beat(4)33.79%
Revenue beat(8)2
Avg Revenue beat(8)-6.52%
Revenue beat(12)4
Avg Revenue beat(12)566.54%
Revenue beat(16)6
Avg Revenue beat(16)430.97%
PT rev (1m)14.71%
PT rev (3m)-24.42%
EPS NQ rev (1m)-3.56%
EPS NQ rev (3m)12.08%
EPS NY rev (1m)-18.26%
EPS NY rev (3m)27.62%
Revenue NQ rev (1m)66.67%
Revenue NQ rev (3m)19.6%
Revenue NY rev (1m)19.12%
Revenue NY rev (3m)39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.99
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS1.26
BVpS3.56
TBVpS3.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.98%
ROE -56.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.77
Quick Ratio 6.77
Altman-Z -2.49
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)43.21%
Cap/Depr(5y)98.7%
Cap/Sales(3y)1.42%
Cap/Sales(5y)453.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-7.36%
EPS Next 2Y5.33%
EPS Next 3Y-6.24%
EPS Next 5Y16.74%
Revenue 1Y (TTM)4.56%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-83.4%
Revenue Next 2Y-57.83%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y20.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.88%
OCF growth 3YN/A
OCF growth 5YN/A